On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
Study limitation reported by the research below: “Overall survival data are immature at this publication; the OS result (HR 0.96) should be interpreted cautiously and not used as a primary efficacy conclusion.”